Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy

Inclusion Criteria: * Unresectable HCC patients were diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of HCC or by pathology * Patients who received SBRT plus TACE have tumor regression, and surgical experts assess that R0 resection could be achieved * CP-A or B classification; * Eastern Cooperative Oncology Group (ECOG) score 0-1; * Platelet count≥50 × 109/L, white blood count≥1.5 × 109/L; * ICG R15≤10%; * Normal effective liver volume \>30%; * patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative. Exclusion Criteria: -the patients receive other treatments (such as targeted treatment, immune checkpoint inhibitors,etc) after CK-SBRT plus TACE.